Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Citigroup Inc.

Citigroup Inc. boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 9.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 177,843 shares of the company's stock after buying an additional 15,859 shares during the quarter. Citigroup Inc. owned approximately 0.31% of Harmony Biosciences worth $7,114,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Lazard Asset Management LLC increased its stake in Harmony Biosciences by 98.3% in the first quarter. Lazard Asset Management LLC now owns 4,542 shares of the company's stock valued at $152,000 after purchasing an additional 2,251 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Harmony Biosciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,219 shares of the company's stock worth $478,000 after acquiring an additional 1,201 shares in the last quarter. Janus Henderson Group PLC lifted its position in Harmony Biosciences by 1,011.7% in the first quarter. Janus Henderson Group PLC now owns 185,083 shares of the company's stock valued at $6,214,000 after acquiring an additional 168,434 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Harmony Biosciences in the second quarter valued at $138,000. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Harmony Biosciences by 214.1% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 44,945 shares of the company's stock valued at $1,356,000 after acquiring an additional 30,638 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday, October 29th. Raymond James reiterated an "outperform" rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Mizuho raised their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research report on Thursday, October 10th. UBS Group initiated coverage on shares of Harmony Biosciences in a report on Tuesday, September 10th. They issued a "buy" rating and a $56.00 target price on the stock. Finally, Oppenheimer reiterated an "outperform" rating and set a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $47.00.

Harmony Biosciences Price Performance

NASDAQ HRMY traded down $1.08 during mid-day trading on Friday, hitting $34.67. The stock had a trading volume of 225,964 shares, compared to its average volume of 796,719. The company has a 50 day simple moving average of $35.16 and a 200 day simple moving average of $33.72. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 16.43, a P/E/G ratio of 0.64 and a beta of 0.77. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter in the previous year, the company posted $0.63 EPS. The business's revenue was up 16.0% on a year-over-year basis. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current fiscal year.

Insider Activity

In other news, insider Jeffrey Dierks sold 21,496 shares of the company's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 30.80% of the company's stock.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.